Company intelligence / Profile preview

Viralytics Ltd

Sydney, New South Wales, Australiaviralytics.digital ↗

Ownership: Private
Development stage: Phase 2

Overview

CAVATAK showed favorable results in Phase 2 CALM trial for advanced melanoma completed in 2015. Multiple trials were underway at the time of acquisition to establish various indications for CAVATAK.

Therapeutic areas: Oncology
Modalities: Oncolytic viruses
Industry: Biotech

Drug pipeline

1 asset

CAVATAK

Phase 2

Indications: Melanoma, Prostate cancer, Lung cancer, Bladder cancer

Partnerships

Merck & Co. (agreement announced in November 2015 to investigate CAVATAK and Keytruda combination)

Beyond the preview

Go deeper on Viralytics Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viralytics Ltd.

Explore the full profile